Oncoliq develops a liquid biopsy method utilizing microRNA detection for the early diagnosis of breast, prostate, and other cancers through a simple blood test. This technology addresses the critical issue of late cancer detection, aiming to identify up to 50 types of cancer, thereby significantly improving treatment outcomes and reducing mortality rates.
Funding
$840K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer screening methods often fail to detect the disease in its early stages when treatment is most effective, leading to higher mortality rates. Traditional screening methods may also be invasive or costly, limiting their accessibility and frequency of use.
Solution
Oncoliq is developing a multi-cancer early detection liquid biopsy that utilizes microRNA (miRNA) analysis and machine learning to identify cancer at an early stage through a simple blood test. By isolating and analyzing miRNAs, which are indicative of various cancers, the test aims to detect up to 50 different types of cancer. The technology employs real-time PCR, a cost-effective and widely used technology, to enable early detection, non-invasive screening, and patient follow-up. The high sensitivity of the technology makes it suitable for monitoring patients during and after cancer treatment.
Target Audience
The primary target audience includes individuals undergoing annual checkups, healthcare providers, and patients requiring regular monitoring for cancer recurrence.
Features
- Utilizes microRNA (miRNA) isolation from blood samples for cancer detection.
- Employs real-time PCR technology for low-cost and rapid analysis.
- Applies machine learning algorithms to analyze miRNA profiles for early cancer detection.
- Designed for non-invasive screening through liquid biopsies.
- Intended for early detection of up to 50 different types of cancer.
- Suitable for patient follow-up during and after cancer treatment.